微信扫码关注“小狗文献”

即刻体验更多权益

文献多,下载快,翻译准

首页 > 医学词汇大全 > B-cell chronic lymphoproliferative disorders (BCLPD)
B-cell chronic lymphoproliferative disorders (BCLPD)

免疫

关键词免疫 疾病 慢性B淋巴细胞增殖病

词汇介绍

拓展阅读

解析

chronic  英  /ˈkrɒnɪk/  美  /ˈkrɑːnɪk/

释    义   adj. 慢性的;长期的;习惯性的

例    句   He was suffering from chronic bronchitis.他患有慢性支气管炎。

 

lymphoproliferative 英  /'lɪmphəprəlɪfərətɪv/  美  /'lɪmphəprəlɪfərətɪv/

释    义   adj. 淋巴组织增生的

例    句   Objective to explore the clinical features and histopathologic classification of ocular adnexal lymphoproliferative lesions in the elderly population.分析老年眼附属器淋巴组织增生性疾病的临床特点及病理分类。

 

disorder  英  /dɪsˈɔːdə(r)/  美  /dɪsˈɔːrdər/

释    义   n. 混乱;骚乱;

               vt. 使失调;扰乱

例    句   The room was in a state of disorder.房间凌乱不堪。

概述

  慢性B淋巴细胞增殖性疾病(BCLPD)是一组在细胞形态学和免疫表型上具有成熟淋巴细胞特征的克隆性淋巴细胞增殖性疾病,临床进程主要表现为惰性过程,是一类很广泛的疾病,主要包括慢性淋巴细胞白血病、毛细胞白血病、边缘区淋巴瘤、滤泡型淋巴瘤、套细胞淋巴瘤以及淋巴浆细胞淋巴瘤/华氏巨球蛋白血症。正确诊断BCLPD必须要结合临床特征、形态学、免疫表型、细胞遗传学和受累组织的病理学等方面综合考虑.   B-CLPD的临床特点  

The Advent of CAR T-Cell Therapy for Lymphoproliferative Neoplasms: Integrating Research Into Clinical Practice.复制标题

CAR T细胞治疗淋巴增殖性肿瘤的出现: 将研究纳入临床实践。

发表时间:2020-05-12

影响因子:4.7

作者: Cerrano M

期刊:Front Immunol

Research on CAR T cells has achieved enormous progress in recent years. After the impressive results obtained in relapsed and refractory B-cell acute lymphoblastic leukemia and aggressive B-cell lymphomas, two constructs, tisagenlecleucel and axicabtagene ciloleucel, were approved by FDA. The role of CAR T cells in the treatment of B-cell disorders, however, is rapidly evolving. Ongoing clinical trials aim at comparing CAR T cells with standard treatment options and at evaluating their efficacy earlier in the disease course. The use of CAR T cells is still limited by the risk of relevant toxicities, most commonly cytokine release syndrome and neurotoxicity, whose management has nonetheless significantly improved. Some patients do not respond or relapse after treatment, either because of poor CAR T-cell expansion, lack of anti-tumor effects or after the loss of the target antigen on tumor cells. Investigators are trying to overcome these hurdles in many ways: by testing constructs which target different and/or multiple antigens or by improving CAR T-cell structure with additional functions and synergistic molecules. Alternative cell sources including allogeneic products ( CAR T cells), NK cells, and T cells obtained from induced pluripotent stem cells are also considered. Several trials are exploring the curative potential of CAR T cells in other malignancies, and recent data on multiple myeloma and chronic lymphocytic leukemia are encouraging.

译文

近年来,CAR - T细胞的研究取得了巨大的进展。在对复发和难治性b细胞急性淋巴细胞白血病和侵袭性b细胞淋巴瘤取得令人印象深刻的结果后,两种结构的组织细胞白血病和阿西卡巴达尼·西莱卢格尔被FDA批准。然而,CAR - T细胞在治疗b细胞疾病中的作用正在迅速发展。正在进行的临床试验旨在比较CAR T细胞和标准治疗方案,并评估它们在病程早期的疗效。CAR - T细胞的使用仍然受到相关毒性风险的限制,最常见的是细胞因子释放综合征和神经毒性,尽管如此,其管理仍有显著改善。部分患者治疗后无应答或复发,原因可能是CAR -t细胞扩增不良、缺乏抗肿瘤作用或肿瘤细胞靶抗原丢失。研究人员正试图通过多种方式克服这些障碍:通过测试以不同和/或多种抗原为靶标的结构,或者通过附加功能和增效分子来改善CAR t细胞结构。其他的细胞来源,包括异基因产物(CAR T细胞),NK细胞,和T细胞诱导多能干细胞也被考虑。一些试验正在探索CAR - T细胞在其他恶性肿瘤中的治疗潜力,最近关于多发性骨髓瘤和慢性淋巴细胞白血病的数据令人鼓舞。